Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | DGKA | P23743 | 2/20 | 0.64 |
| ▸ | PAM | P19021 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 4/20 | 0.53 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | PRKCA | P17252 | 1/20 | 0.49 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.49 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.49 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20570495 | 1.00 | TSHR (0.70) | TSHRDGKAPAMMAPTLMNA | |
| SCHEMBL22126641 | 1.00 | TSHR (0.70) | TSHRDGKAPAMMAPTLMNA | |
| SCHEMBL22126648 | 1.00 | TSHR (0.70) | TSHRDGKAPAMMAPTLMNA | |
| SCHEMBL5668563 | 1.00 | TSHR (0.70) | TSHRDGKAPAMMAPTLMNA | |
| SCHEMBL22126642 | 1.00 | TSHR (0.70) | TSHRDGKAPAMMAPTLMNA | |
| SCHEMBL22126638 | 1.00 | TSHR (0.70) | TSHRDGKAPAMMAPTLMNA | |
| SCHEMBL5666555 | 0.98 | TSHR (0.67) | TSHRDGKAPAMMAPTLMNA | |
| SCHEMBL250417 | 0.92 | TSHR (0.58) | TSHRDGKAPAMMAPTLMNA | |
| SCHEMBL18036999 | 0.91 | DGKA (0.60) | TSHRDGKAMAPTLMNADUSP3 | |
| SCHEMBL11507812 | 0.87 | TSHR (0.50) | TSHRDGKAPAMMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 917 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024110037-A1 | VEGAN-BASED WHOLE EGG SUBSTITUTE PRODUCT | NEGGST FOODS GMBH (DE) | 2024-05-30 | — | — | WO | claimed |
| WO-2024110038-A1 | VEGAN-BASED EGG SUBSTITUTE PRODUCT | NEGGST FOODS GMBH (DE) | 2024-05-30 | — | — | WO | claimed |
| WO-2023094536-A1 | VEGAN-BASED EGG YOLK SUBSTITUTE PRODUCT | NEGGST FOODS GMBH (DE) | 2023-06-01 | — | — | WO | claimed |
| EP-3644968-A1 | LEVOCLOPERASTINE FENDIZOATE SUSPENSION HAVING ENHANCED DISSOLUTION AND RESUSPENDABILITY | Ilko Ilaç Sanayi Ve Ticaret Anonim Sirketi (TR) | 2020-05-06 | — | — | EP | claimed |
| WO-2019004953-A1 | LEVOCLOPERASTINE FENDIZOATE SUSPENSION HAVING ENHANCED DISSOLUTION AND RESUSPENDABILITY | İLKO ILAÇ SANAYI VE TICARET ANONIM ŞIRKETI (TR) | 2019-01-03 | — | — | WO | claimed |
| US-9968548-B2 | Dental hard chew supplements containing antimicrobial actives | VETS PLUS, INC. (US) | 2018-05-15 | — | — | US | claimed |
| US-20160128932-A1 | DENTAL HARD CHEW SUPPLEMENTS CONTAINING ANTIMICROBIAL ACTIVES | VETS PLUS, INC. (US) | 2016-05-12 | — | — | US | claimed |
| US-20140044788-A1 | Solid Oral Formulations of a Pyridopyrimidinone | NOVARTIS AG (CH) | 2014-02-13 | — | — | US | claimed |
| US-20110287069-A1 | SOLID ORAL FORMULATIONS OF A PYRIDOPYRIMIDINONE | NOVARTIS AG (CH) | 2011-11-24 | — | — | US | claimed |
| WO-2010088336-A1 | SOLID ORAL FORMULATIONS OF A PYRIDOPYRIMIDINONE | NOVARTIS AG (CH) | 2010-08-05 | — | — | WO | claimed |
| US-20090155352-A1 | Microemulsion containing indolocarbazole compound and dosage forms containing the same | CEPHALON, INC. (US) | 2009-06-18 | — | — | US | claimed |
| WO-2009067221-A2 | MICROEMULSION CONTAINING INDOLOCARBAZOLE COMPOUND AND DOSAGE FORMS CONTAINING THE SAME | CEPHALON, INC. (US) | 2009-05-28 | — | — | WO | claimed |
| WO-2004098562-A2 | CONTROLLED RELEASE SOLID DOSAGE NIFEDIPINE FORMULATIONS | NOVEON IP HOLDINGS CORP. (US) | 2004-11-18 | — | — | WO | claimed |
| US-20040219210-A1 | Controlled release solid dosage nifedipine formulations | LUBRIZOL ADVANCED MATERIALS, INC. | 2004-11-04 | — | — | US | claimed |
| WO-2003084513-A1 | CONTROLLED RELEASE SOLID DOSAGE CARBAMAZEPINE FORMULATIONS | NOVEON IP HOLDINGS CORP. (US) | 2003-10-16 | — | — | WO | claimed |
| US-6572889-B1 | Crosslinked polymer of an unsaturated acid | NOVEON IP HOLDINGS CORP. | 2003-06-03 | — | — | US | claimed |
| EP-0206244-A2 | Magnetic disc | Hitachi Maxell Ltd. (JP) | 1986-12-30 | — | — | EP | claimed |
| US-12024510-B2 | Pyrazolopyridine-diamides, their use as insecticide and processes for preparing the same | PI INDUSTRIES LTD. (IN) | 2024-07-02 | — | — | US | disclosed |
| US-4857336-A | Oral therapeutic system having systemic action | CIBA-GEIGY CORPORATION (US) | 1989-08-15 | — | — | US | disclosed |
| US-4826842-A | TRIAZINETRIONE DERIVATIVE | BAYER AKTIENGESELLSCHAFT (DE) | 1989-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12024510-B2 | Pyrazolopyridine-diamides, their use as insecticide and processes for preparing the same | DDT, QDPR, CYP1A1 | TSHR 2093/4885DGKA 1140/4885PAM 1126/4885 |
| US-20090155352-A1 | Microemulsion containing indolocarbazole compound and dosage forms containing the same | MAP1LC3B, IDO1, IL33 | TSHR 2436/4885DGKA 2632/4885PAM 3872/4885 |
| US-20140044788-A1 | Solid Oral Formulations of a Pyridopyrimidinone | PLPBP, DPYD, SLC7A1 | TSHR 1436/4885DGKA 4607/4885PAM 279/4885 |
| US-20110287069-A1 | SOLID ORAL FORMULATIONS OF A PYRIDOPYRIMIDINONE | PLPBP, DPYD, SLC7A1 | TSHR 1436/4885DGKA 4607/4885PAM 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.